Brian Horsburgh Email & Phone Number

Connecticut, United States

Activate is developing drugs to reprogram tumor associated macrophages.

Immunova is a development-stage company whose mission is to achieve therapeutic success by attacking multiple disease targets simultaneously. Our nanotechnology permits delivery of different drug combinations to the disease microenvironment.

MindNest Health is a digital health company whose mission is to increase access to high quality care for children with autism and other behavioural disorders.

We are a venture-backed business, working with Eli Lilly Chorus, and focused on modulating the immune system for cancer therapy using IL-2 and TGF-b inhibitors delivered to the tumor microenvironment. Our lead compound will be tested in patients with metastatic cancer.

NeuroNetworks Fund is a 501C3 venture philanthropy fund focused on providing capital and business building know-how to translate innovation in the neurodisorder arena (Autism, Epilepsy, and Schizophrenia).https://www.facebook.com/pg/NeuroNetworksFund/posts/?ref=page_internalhttps://twitter.com/NeuroNetworks

Providing advice on early stage investment, commercialisation of intellectual property, as well as interim management in life science businesses.

Bethesda, Maryland, US

Epidarex Capital (formerly Rock Spring Ventures) invests in early-stage, high growth life science and health technology companies in under-ventured markets within the UK and US. Epidarex funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today’s healthcare market.

Union Life Sciences focuses on the scientific and commercial development and licensing of early stage drug candidates sourced from Universities throughout Europe

IP Group plc raises funds from the capital markets and invests in IP businesses that originated from UK universities. The company has a portfolio of circa 64 companies, 16 of which have been floated on the London Stock Exchanges.

Providing commercial advice and interim management for IP Group life science portfolio companies

Azellon is a clinical stage an autologous stem cell medical device company focusing on living bandages for meniscal knee repair

Mode Diagnostics (www.ModeDx.com) is a development company focused on integrating biosensing and electronics to produce diagnostic devices for the home-based point-of-care markets in China and the UK

Amaethon is the commercialization arm of the Centre of Novel Agricultural Products at York University focusing on plants for biorenewable feedstocks, health and phytoremediation.

ReactivLab is a company focusing on the well being of animals and specialises in the diagnosis and prognosis of illness based on the analysis of specific biomarker proteins, notably the acute phase proteins. Reactivlab was acquired by Avacta plc.

Xanic is set to become Europe's leading supplier of commercial high-frequency components for applications in the aerospace/defence and homeland security markets.

Identification of university-based innovation with a substantial market need, creation and portfolio management of next generation high technology companies timing their exits on a risk adjusted valuation

GB

Search and evaluation of technologies and evaluation of technology business models in healthcare

Developing and commercializing Nerve-Release Therapy (Nurel Therapy) products for the treatment of Pain and Neuropathy. Nurel was acquired by Diamyd AB.

Developing and commercializing novel viral-based therapeutics for oncology

Developing and commercializing novel viral-based products for oncology and CNS indications. Neurovir was acquired by Medigene AG.

Boston, MA, US

Investigating mechanisms of anti-viral drug resistance in immunocompromised patient populations

Fellow, Biological Chemistry And Molecular Pharmacology

Phd, Virology - Coronavirus Vaccines

Bsc (Hons), Molecular Biology